Late Friday, several key board members have resigned from Mydecine Innovations Group. What does this mean for this company? From worrisome cash flow, to a recent reverse stock split, and a lack of advancement in their clinical trials, the firm has been leaving investors with a great many questions.
Without further explanation, the simultaneous resignation of several key board members does not seem to signal positive news. Stay tuned for more as the story unfolds.
MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS
DENVER, Aug. 12, 2022 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale have recently resigned as directors of the Company.
The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency.
The Company would like to express their gratitude to Mr. Michaels, Ms. Wu, Dr. Babaei, and Dr. Hale for all of the valuable contributions they have made to the company and wish them the best of luck in all of their future endeavors. Mr. Michaels will continue to serve as Chief Operating Officer for the organization. As a result of the resignations, the Company is currently searching for candidates with a background in drug development to fill two board positions. Josh Bartch, Rob Roscow, and Todd Heinzl have the best interest of the company’s stockholders and will continue to serve on the board for the foreseeable future.
About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine’s dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world’s leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine’s approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise. Headquartered in Colorado, USA, Mydecine was founded in 2020, with offices in Alberta, Canada, and Leiden, Netherlands.
Learn more at: https://www.mydecine.com/
and follow us on Facebook, Twitter, and Instagram.
On behalf of the Board of Directors
Joshua Bartch, Chaiman and CEO
contact@mydecineinc.com
For further information about Mydecine, please visit the Company’s profile on SEDAR at https://sedar.com/ or visit the Company’s website at https://www.mydecine.com/.